Monitor for future clinical data readouts from the partnership and any expansion of commercial sites. The partnership adds a high-volume referral center but does not change the near-term revenue trajectory without disclosed financial terms.
Price Chart
Executive Summary
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers commercial use of the nPulse Vybrance Percutaneous Electrode System for treating benign thyroid nodules and a clinical collaboration to generate outcomes data. This is a routine commercial expansion and clinical data-generation event with no financial terms disclosed.
Key Facts
- Partnership with Clayman Thyroid Center at Hospital for Endocrine Surgery in Tampa, FL
- Covers commercial use of nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules
- Includes clinical collaboration to collect real-world outcomes and conduct formal clinical studies
- Clayman Thyroid Center is described as one of the largest thyroid surgery centers in the US with regional and national referral patterns
- No financial terms, revenue guidance, or material financial impact disclosed
Financial Impact
No financial terms disclosed in the filing
Risk Factors
- Clinical data may not support expanded adoption or regulatory clearances
- Competitive PFA technologies may gain market share in thyroid nodule treatment
- No disclosed financial commitment or minimum purchase obligations from the partner
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032601 |
| Exhibit: ex_1025477.htm | 0001437749-26-032601 |
| Document: 0001437749-26-032601-index-headers.html | 0001437749-26-032601 |
| Document: 0001437749-26-032601-index.html | 0001437749-26-032601 |
| Document: 0001437749-26-032601.txt | 0001437749-26-032601 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $46.32 | awaiting T+60 | — | $53.02 (+14.46%) |
Oct 7, 2026 19d ago | 8-K | $49.09 | awaiting T+60 | — | $53.02 (+8.01%) |
Sep 15, 2026 5w ago | 8-K | $55.20 | awaiting T+60 | — | $53.02 (−3.95%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $53.02 (−25.02%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $53.02 (−25.02%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $53.02 (+54.80%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $53.02 (+117.56%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $53.02 (+112.16%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $53.02 (+107.03%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $53.02 (+177.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers